4Tissue Recognized as a Leading Regenerative Medicine Company in Europe

We are thrilled and deeply honored to announce that 4Tissue has been recognized as one of the Top Regenerative Medicine Companies in Europe – 2025 by Life Sciences Review.

This recognition underscores our groundbreaking work in redefining breast reconstruction through our innovative, bioresorbable injectable hydrogel tissue mimic — a solution designed to support natural regeneration, minimize scarring, and reduce the need for repeated surgeries.

By encapsulating a patient's own adipose or stem cells, our platform enhances cell survival and accelerates vascular growth. Over approximately six months, the hydrogel safely resorbs, leaving behind fully natural tissue.

As Dr. An Van Den Bulckee, CEO a.i. and co-founder, emphasizes:
"Our hydrogel platform isn't just about reconstructing tissue; it's redefining the future of soft-tissue regeneration. We make it safer, simpler, and truly patient-centered."

This achievement reflects the dedication of our multidisciplinary team — polymer chemists, surgeons, regulatory specialists, and clinical experts — whose collaboration continues to drive innovation forward.

We extend our sincere gratitude to our partners, collaborators, and investors who share our vision. This award reaffirms our collective commitment to transforming women's health and marks an exciting milestone as we advance toward impactful clinical outcomes and beyond.